For most CEOs who need to raise cash, what you say is right...a lack of capital is always a big deal.  Keeps them awake all night.

With RVX however, DM has a trump card: Hepalink.  He can always go to them in a pinch, if need be.

Although Hepalink is a $4 billion market cap company, they don't have that much cash in the balance sheet.  However, given that it is a Chinese company, and a certified biotech success story (can't say that about 99.999% of Chinese biotech companies; it is not even clear that China biotech companies are actually "biotech"), their ability to source cash can't be too much of an issue, particularly if it is only $10 to $15 million.

And that is what keeps DM managing to dodge many bullets...so far.